{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-003555","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.799212+00:00","generated_at":"2026-06-20T18:48:29.929579+00:00","sec_items":["2.03","1.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atara Bio closes $31M royalty financing liability with HCR Molag Fund","bullets":["Closed $31M royalty financing with HCR Molag Fund on Dec 30, 2022; recorded net of transaction costs.","Financing stems from Purchase and Sale Agreement dated Dec 20, 2022, previously disclosed.","Transaction creates a direct financial obligation under Item 2.03 of Form 8-K.","HCR Molag Fund, L.P. is the counterparty; net proceeds used for general corporate purposes (not specified)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-003555","json":"https://secwatch.observer/filing/0001193125-23-003555.json","markdown":"https://secwatch.observer/filing/0001193125-23-003555.md","text":"https://secwatch.observer/filing/0001193125-23-003555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/0001193125-23-003555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/d444758d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:48:29.929579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f43a6db988a104a7c8f3abe71ac5114cb57ca12d","claim":"Atara Biotherapeutics, Inc. incurred debt of $31,000,000, net of certain transaction costs with HCR Molag Fund, L.P..","evidence_excerpt":"On December 30, 2022, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and HCR Molag Fund, L.P., a Delaware limited partnership (“HCR”), closed the transactions contemplated by that certain Purchase and Sale Agreement dated December 20, 2022 by and between the Company and HCR.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/0001193125-23-003555-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"$31,000,000, net of certain transaction costs"},{"label":"Counterparty","value":"HCR Molag Fund, L.P."},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}